Abstract
c-JUN-N-terminal kinase (JNK) signaling is a stress-induced response that enables survival of normal cells and is also utilized by cancer cells to evade therapy. Combining JNK inhibitors with standard therapies provides a potential strategy for overcoming drug resistance. Use of the optimal combination dosing and scheduling may substantially improve outcomes for cancer patients.
Original language | English |
---|---|
Article number | e1128515 |
Journal | Molecular and Cellular Oncology |
Volume | 3 |
Issue number | 3 |
DOIs |
|
Publication status | Published or Issued - 3 May 2016 |
Externally published | Yes |
Keywords
- Combination therapies
- EMT
- JNK signaling
- dosing
- drug resistance
- early adaptation
- phenotype-switching
- scheduling
- stress response
ASJC Scopus subject areas
- Molecular Medicine
- Cancer Research